Idiopathic pulmonary fibrosis

L Richeldi, HR Collard, MG Jones - The Lancet, 2017 - thelancet.com
Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …

Palliative care in interstitial lung disease: living well

M Kreuter, E Bendstrup, AM Russell… - The Lancet …, 2017 - thelancet.com
Progressive fibrotic interstitial lung diseases (ILDs) are characterised by major reductions in
quality of life and survival and have similarities to certain malignancies. However, palliative …

Do patients want to die at home? A systematic review of the UK literature, focused on missing preferences for place of death

S Hoare, ZS Morris, MP Kelly, I Kuhn, S Barclay - PloS one, 2015 - journals.plos.org
Background End-of-life care policy has a focus on enabling patients to die in their preferred
place; this is believed for most to be home. This review assesses patient preferences for …

Palliative care and location of death in decedents with idiopathic pulmonary fibrosis

KO Lindell, Z Liang, LA Hoffman, MQ Rosenzweig… - Chest, 2015 - Elsevier
BACKGROUND Palliative care, integrated early, may reduce symptom burden in patients
with idiopathic pulmonary fibrosis (IPF). However, limited information exists on timing and …

The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals

S Bajwah, IJ Higginson, JR Ross, AU Wells… - Palliative …, 2013 - journals.sagepub.com
Background: While there have been some studies looking at the impact on quality of life of
patients with idiopathic pulmonary fibrosis, to date no qualitative research looking at the …

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries

TM Maher, M Molina-Molina, AM Russell… - BMC pulmonary …, 2017 - Springer
Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the
European Medicines Agency and the US Food and Drug Administration for the treatment of …

Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention

S Bajwah, JR Ross, AU Wells, K Mohammed… - Thorax, 2015 - thorax.bmj.com
Background Those affected by advanced fibrotic interstitial lung diseases (ILDs) have
considerable unmet symptom and psychological needs. Case conferencing has been …

End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study

Z Ahmadi, NG Wysham, S Lundström, C Janson… - Thorax, 2016 - thorax.bmj.com
Rationale Advanced fibrosing interstitial lung disease (ILD) is often progressive and
associated with a high burden of symptoms and poor prognosis. Little is known about the …

End-of-life care of patients with idiopathic pulmonary fibrosis

K Rajala, JT Lehto, M Saarinen, E Sutinen, T Saarto… - BMC palliative …, 2016 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease with median
survival from 2 to 7 years. Palliative care is an important part of patients´ care as lung …

Inadequate palliative care in chronic lung disease. An issue of health care inequality

CE Brown, NS Jecker, JR Curtis - Annals of the American Thoracic …, 2016 - atsjournals.org
Patients with chronic lung diseases suffer higher symptom burden, lower quality of life, and
greater social isolation compared with patients with other diagnoses, such as cancer. These …